RECCE PHARMACEUTICALS LTD — Director's Dealing 2023

Oct 5, 2023

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Recce Pharmaceuticals Ltd (Company)
ABN	73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Graham
Date of last notice	26 June 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect interest
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	Mr. James Grahamis the trusteeof the JGraham Family Trust and a beneficiary of thetrustButtonwood Nominees Pty Ltd held on behalfof Mr James GrahamBulleen Pty Ltd an entity controlled by MrGraham
Date of change	29 September 2023

+ See chapter 19 for defined terms.

No. of securities held prior to change	Total number of fully paid ordinary sharesheld prior to change: 6,531,932
	Direct Interest
	1.262,347 fully paid ordinary shares
	2.389,712 Class B Performance Shares
	3.2,250,000 Unlisted Options
	Indirect Interest
	Mr. James Graham
	4.356,250 Class B Performance Shares
	Buttonwood Nominees Pty Ltd
	5.5,500,000 fully paid ordinary shares
	Bulleen Pty Ltd
	6.769,585 fully paid ordinary shares
Class	Fully paid ordinary shares
Number acquired	233,430 fully paid ordinary shares
Number disposed	Nil
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	$0.44 (44 cents) per fully paid ordinary share
No. of securities held after change	Total number of fully paid ordinary sharesheld after change: 6,765,362
	Direct Interest1.389,712 Class B Performance Shares
	2.2,250,000 Unlisted Options
	Indirect Interest
	Mr. James Graham
	3.356,250 Class B Performance Shares
	Buttonwood Nominees Pty Ltd
	4.6,765,362 fully paid ordinary shares
Nature of change	ParticipationintheCompany'snon
Example: on-market trade, off-market trade, exercise of options, issue	renounceablepro rataEntitlement Offer as
of securities under dividend reinvestment plan, participation in buyback	announced by the Company on 11 September
	2023
	Transfer of shares from direct holdings and
	entities controlled by Mr Grahamhowever
	there was no change in Mr Graham's relevant
	interest as a result of the transfers.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

+ See chapter 19 for defined terms.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to whichinterest related prior to changeNote: Details are only required for acontract in relation to which theinterest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash,provide details and an estimatedvaluation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed abovetraded during a +closed periodwhere prior written clearancewas required?	N/A
If so, was prior written clearance provided to allow the trade toproceed during this period?	N/A
If prior written clearance was provided, on what date was thisprovided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Recce Pharmaceuticals Ltd (Company)
ABN	73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Justin Ward
Date of last notice	25 February 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	N/A
Date of change	29 September 2023
No. of securities held prior to change	158,966 fully paid ordinary shares600,000 unlisted options each exercisable as$1.56, expiring 22 February 2026
Class	Fully paid ordinary shares
Number acquired	6,114 fully paid ordinary shares
Number disposed	Nil
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	$0.44 (44 cents) per fully paid ordinary share
No. of securities held after change	165,080 fully paid ordinary shares
	600,000 unlisted options each exercisable as$1.56, expiring 22 February 2026

+ See chapter 19 for defined terms.

Nature of changeExample: on-market trade, off-market trade, exercise of options, issueof securities under dividend reinvestment plan, participation in buyback	ParticipationintheCompany'snonrenounceablepro rata Entitlement Offer asannounced by the Company on 11 September2023

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to whichinterest related prior to changeNote: Details are only required for acontract in relation to which theinterest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash,provide details and an estimatedvaluation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed abovetraded during a +closed periodwhere prior written clearancewas required?	N/A
If so, was prior written clearance provided to allow the trade toproceed during this period?	N/A
If prior written clearance was provided, on what date was thisprovided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Recce Pharmaceuticals Ltd (Company)
ABN	73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Alistair McKeough
Date of last notice	15 November 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	Finn Frist Pty Ltd as trustee for the AZMSuperannuation Fund of which Mr McKeoughis a director and shareholder of the trustee anda beneficiary of the trust (Finn Frist Pty Ltd)
	AmabelPtyLimitedastrusteefortheMcKeoughFamilyTrustofwhichMrMcKeough is a director of the trustee and abeneficiary of the trust (Amabel Pty Limited)
Date of change	29 September 2023
No. of securities held prior to change	Finn Frist Pty Ltd1.25,000 fully paid ordinary sharesAmabel Pty Limited2.1,125,000unlistedoptionseachexercisableas$1.56,expiring15November 2027
Class	Fully paid ordinary shares
Number acquired	961 fully paid ordinary shares
Number disposed	Nil

+ See chapter 19 for defined terms.

Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	$0.44 (44 cents) per fully paid ordinary share
No. of securities held after change	Finn Frist Pty Ltd1.25,961 fully paid ordinary sharesAmabel Pty Limited2.1,125,000unlistedoptionseachexercisableas$1.56,expiring15November 2027
Nature of changeExample: on-market trade, off-market trade, exercise of options, issueof securities under dividend reinvestment plan, participation in buyback	ParticipationintheCompany'snonrenounceablepro rata Entitlement Offer asannounced by the Company on 11 September2023.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)
Date of change	N/A
No. and class of securities to whichinterest related prior to changeNote: Details are only required for acontract in relation to which theinterest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash,provide details and an estimatedvaluation	N/A
Interest after change	N/A

Part 3 – +Closed period

+ See chapter 19 for defined terms.

Were the interests in the securities or contracts detailed abovetraded during a +closed periodwhere prior written clearancewas required?	N/A
If so, was prior written clearance provided to allow the trade toproceed during this period?	N/A
If prior written clearance was provided, on what date was thisprovided?	N/A

+ See chapter 19 for defined terms.